Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.57 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851438 | 0.87 | P2RY12 (0.49) | P2RY12HTR6MEN1GBA1 | |
| SCHEMBL5849362 | 0.87 | P2RY12 (0.49) | TLR9P2RY12HTR6MEN1GBA1 | |
| SCHEMBL7051316 | 0.87 | HTR6 (0.64) | P2RY12HTR6MEN1GBA1 | |
| SCHEMBL4914250 | 0.86 | P2RY12 (0.49) | P2RY12HTR6MEN1GBA1 | |
| SCHEMBL4723775 | 0.86 | P2RY12 (0.49) | P2RY12HTR6MEN1GBA1 | |
| SCHEMBL7062150 | 0.86 | HTR6 (0.52) | P2RY12HTR6MEN1 | |
| SCHEMBL5851018 | 0.85 | P2RY12 (0.48) | P2RY12HTR6MEN1GBA1 | |
| SCHEMBL5851554 | 0.85 | P2RY12 (0.48) | TLR9P2RY12HTR6MEN1 | |
| SCHEMBL5850446 | 0.85 | MAPT (0.50) | TLR9P2RY12HTR6MEN1 | |
| SCHEMBL5849520 | 0.84 | P2RY12 (0.49) | P2RY12HTR6MEN1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |